Effects of age and sex on single-dose pharmacokinetics of tigecycline in healthy subjects

Antimicrobial Agents and Chemotherapy

Volumn 49, Issue 4, 2005, Pages 1656-1659

  Muralidharan, Gopal ^a,b   Fruncillo, Richard J ^a   Micalizzi, Marlynne ^a   Raible, Donald G ^a   Troy, Steven M ^a  

^a PFIZER INC   (United States)

^b Lotus Labs Private Ltd   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; TIGECYCLINE;

ADULT; AGE; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG URINE LEVEL; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NAUSEA; NORMAL HUMAN; OPEN STUDY; PRIORITY JOURNAL; SEX DIFFERENCE; SIDE EFFECT; SINGLE DRUG DOSE; STEADY STATE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AGING; AREA UNDER CURVE; FEMALE; HUMANS; MALE; MIDDLE AGED; MINOCYCLINE; SEX CHARACTERISTICS;

EID: 16244402970     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.49.4.1656-1659.2005     Document Type: Article

References (26)

1. Betriu, C., E. Culebras, I. Rodriguez-Avial, M. Gomez, B. A. Sanchez, and J. J. Picazo. 2004. In vitro activities of tigecycline against erythromycin-resistant Streptococcuspyogenes and Streptococcus agalactiae: mechanisms of macrolide and tetracycline resistance. Antimicrob. Agents Chemother. 48:323-325.
2. Betriu, C., I. Rodriguez-Avial, B. A. Sanchez, M. Gomez, J. Alvarez, J. J. Picazo, and the Spanish Group of Tigecycline. 2002. In vitro activities of tigecycline (GAR-936) against recently isolated clinical bacteria in Spain. Antimicrob. Agents Chemother. 46:892-895.
3. Biedenbach, D. J., M. L. Beach, and R. N. Jones. 2001. In vitro antimicrobial activity of GAR-936 tested against antibiotic-resistant gram-positive blood stream infection isolates and strains producing extended-spectrum beta-lactamases. Diagn. Microbiol. Infect. Dis. 40:173-177.
4. Cazzola, M., F. Blasi, S. Centanni, C. F. Donner, and L. Allegra. 2001. Advances in the research and development of chemotherapeutic agents for respiratory tract bacterial infections. Pulm. Pharmacol. Ther. 14:367-381.
5. Chopra, I. 2002. New developments in tetracycline antibiotics: glycylcyclines and tetracycline efflux pump inhibitors. Drug Resist. Updates 5:119-125.
6. Deshpande, L. M., A. C. Gales, and R. N. Jones. 2001. GAR-936 (9-t-butylglycylamido-minocycline) susceptibility test development for streptococci, Haemophilus influenzae and Neisseria gonorrhoeae: preliminary guidelines and interpretive criteria. Int. J. Antimicrob. Agents 18:29-35.
7. Edelstein, P. H., W. J. Weiss, and M. A. Edelstein. 2003. Activities of tigecycline (GAR-936) against Legionella pneumophila in vitro and in guinea pigs with L. pneumophila pneumonia. Antimicrob. Agents Chemother. 47:533-540.
8. Edlund, C., and C. E. Nord. 2000. In-vitro susceptibility of anaerobic bacteria to GAR-936, a new glycylcycline. Clin. Microbiol. Infect. 6:159-163.
9. Hockings, N., A. A. Ajayi, and J. L. Reid. 1986. Age and the pharmacokinetics of angiotensin converting enzyme inhibitors enalapril and enalaprilat. Br. J. Clin. Pharmacol. 21:341-348.
10. Jones, R. N. 1999. Disk diffusion susceptibility test development for the new glycylcycline, GAR-936. Diagn. Microbiol. Infect. Dis. 35:249-252.
11. Jusko, W. J. 1992. Guidelines for collection and analysis of pharmacokinetic data, p. 2-1-2-43. In W. E. Evans, J. J. Schentag, and W. J. Jusko (ed.), Applied pharmacokinetics: principles of therapeutic drug monitoring, 3rd ed. Applied Therapeutics, Vancouver, Wash.
12. LaCreta, F. P., G. D. Kollia, G. Duncan, D. Behr, and D. M. Grasela. 2000. Age and gender effects on the pharmacokinetics of gatifloxacin. Pharmacotherapy 20:67S-75S.
13. Lefort, A., M. Lafaurie, L. Massias, Y. Petegnief, A. Saleh-Mghir, C. Muller-Serieys, D. Le Guludec, and B. Fantin. 2003. Activity and diffusion of tigecycline (GAR-936) in experimental enterococcal endocarditis. Antimicrob. Agents Chemother. 47:216-222.
14. Meyers, B. R., and P. Wilkinson. 1989. Clinical pharmacokinetics of antibacterial drugs in the elderly. Implications for selection and dosage. Clin. Pharmacokinet. 17:385-395.
15. Muck, W., H. P. Breuel, and J. Kuhlmann. 1996. The influence of age on the pharmacokinetics of nimodipine. Int. J. Clin. Pharmacol. Ther. 34:293-298.
16. Muhlberg, W., and D. Platt. 1999. Age-dependent changes of the kidneys: pharmacological implications. Gerontology 45:243-253.
17. Muralidharan, G., M. Micalizzi, J. Speth, D. Raible, and S. Troy. 2005. Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects. Antimicrob. Agents Chemother. 49:220-229.
18. Nannini, E. C., S. R. Pai, K. V. Singh, and B. E. Murray. 2003. Activity of tigecycline (GAR-936), a novel glycylcycline, against enterococci in the mouse peritonitis model. Antimicrob. Agents Chemother. 47:529-532.
19. Norrby, S. R., and B. Ljungberg. 1989. Pharmacokinetics of fluorinated 4-quinolones in the aged. Rev. Infect. Dis. 11:51102-51106.
20. Patel, R., M. S. Rouse, K. E. Piper, and J. M. Steckelberg. 2000. In vitro activity of GAR-936 against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae. Diagn. Microbiol. Infect. Dis. 38:177-179.
21. Postier, R. G., S. L. Green, S. R. Klein, E. J. Ellis-Grosse, and E. Loh. 2004. Results of a multicenter, randomized, open-label efficacy and safety study of two doses of tigecycline for complicated skin and skin-structure infections in hospitalized patients. Clin. Ther. 26:704-714.
22. Rasmussen, B. A., Y. Gluzman, and F. P. Tally. 1994. Inhibition of protein synthesis occurring on tetracycline-resistant, TetM-protected ribosomes by a novel class of tetracyclines, the glycylcyclines. Antimicrob. Agents Chemother. 38:1658-1660.
23. Schnappinger, D., and W. Hillen. 1996. Tetracyclines: antibiotic action, uptake, and resistance mechanisms. Arch. Microbiol. 165:359-369.
24. Schwartz, J. B. 2003. The influence of sex on pharmacokinetics. Clin. Pharmacokinet. 42:107-121.
25. + antiporter. Antimicrob. Agents Chemother. 39:247-249.
26. van Ogtrop, M. L., D. Andes, T. J. Stamstad, B. Conklin, W. J. Weiss, W. A. Craig, and O. Vesga. 2000. In vivo pharmacodynamic activities of two glycylcyclines (GAR-936 and WAY 152,288) against various gram-positive and gram-negative bacteria. Antimicrob. Agents Chemother. 44:943-949.